Skip to content

Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial

Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01920685
Acronym
CITADEL
Enrollment
25
Registered
2013-08-12
Start date
2014-01-31
Completion date
2016-10-31
Last updated
2017-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paranoia in People With Schizophrenia-spectrum Diagnosis

Keywords

Paranoia, CBT, Reasoning, Anxiety

Brief summary

People with a schizophrenia spectrum diagnosis often experience distressing worries or beliefs about others intending to cause them harm (also known as paranoia). Paranoid beliefs are associated with significant distress and disruption to the person's life. This results in high use of services and costs to mental health providers. The National Institute of Clinical Excellence recommends that cognitive behavioural therapy for psychosis (CBTp) is offered to everybody with a schizophrenia spectrum psychosis. The latest meta analyses report improved outcomes, and reduced inpatient stays following CBTp, making it a cost effective intervention. Although improved outcomes have been obtained by therapies, CBTp has only small to moderate effects on paranoid beliefs. Further, training therapists to competently deliver CBTp is intensive, expensive and takes up to a year. CBTp is therefore not widely available to service users, resulting in inequalities in access to care. The investigators are seeking to improve outcomes and accessibility of CBTp for people with distressing, paranoid beliefs. The proposed research programme aims to conduct a feasibility study of a brief therapeutic intervention, aimed at targeting and improving anxiety processes that are causally implicated in paranoia (Freeman et al, 2015). The investigators have preliminary evidence indicating that the pilot intervention, with interactive multimedia content, reduced distressing beliefs and improved coping (Freeman et al, 2015). Participants also reported they found the therapy acceptable, enjoyable and useful. Based on these results, the investigators have further modified the intervention. The feasibility and efficacy of the therapy will be investigated in a randomised controlled design (n = 34). Please note the protocol has been been amended to exclude a pilot trial of a second brief intervention targeting reasoning styles in paranoia, as since the initial protocol was developed we have obtained data from two randomised pilot studies demonstrating its feasibility and acceptability (Garety et al, 2015; Waller et al, 2015). A further pilot trial of the reasoning styles intervention is therefore not indicated.

Interventions

Sponsors

King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Self reported worries about being harmed or at risk from others * Non-affective psychosis(ICD10,F20-F29) * Age 18-65 * Symptoms stable no major relapse or crisis in last 3 months prior to consent * Sufficient command of English to provide informed consent, complete the measures and participate in the brief interventions * Score above the cutoff for clinically significant levels of paranoia on the Green Paranoid Thoughts Scale (Green et al, 2008) * Paranoia is triggered by being outside

Exclusion criteria

* Lack of capacity to provide informed consent * Primary diagnosis of drug or alcohol use with secondary psychosis * Primary diagnosis of mood disorder or bipolar affective disorder * Primary diagnosis of learning difficulty * Unstable residential arrangements (making a move away during the course of participation in the research likely)

Design outcomes

Primary

MeasureTime frame
Green Paranoid Thoughts ScaleChange from baseline in paranoia scores at 8 weeks and 12 weeks

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026